The University of Southampton
University of Southampton Institutional Repository

Systematic review: the management of chronic diarrhoea due to bile acid malabsorption

Systematic review: the management of chronic diarrhoea due to bile acid malabsorption
Systematic review: the management of chronic diarrhoea due to bile acid malabsorption
Background
Bile acid malabsorption (BAM) is a common, yet under-recognised, cause of chronic diarrhoea, with limited guidance available on the appropriate management of patients with BAM.

Aim
To summarise the evidence supporting different treatments available for patients with bile acid malabsorption, noting their impact on clinical outcomes, tolerability and associated side effects.

Methods
A literature search was conducted through PubMed, the Cochrane Database of Systematic Reviews and Scopus. Relevant articles studied patients who had been diagnosed with BAM and were clinically assessed before and after therapy.

Results
A total of 30 relevant publications (1241 adult patients) were identified, which investigated the clinical response to drugs, including colestyramine, colestipol, colesevelam, aluminium hydroxide and obeticholic acid. The most commonly used diagnostic test of bile acid malabsorption was the SeHCAT test (24 studies). Colestyramine treatment was by far the most studied of these agents, and was successful in 70% of 801 patients (range: 63–100%).

Conclusions
Colestyramine and colestipol are generally effective treatments of gastrointestinal symptoms from BAM, but may be poorly tolerated and reduce the bioavailability of co-administered agents. Alternative therapies (including colesevelam and aluminium hydroxide) as well as dietary intervention may also have a role, and the promising results of the first proof-of-concept study of obeticholic acid suggest that its novel approach may have an exciting future in the treatment of this condition. Future trials should employ accurate diagnostic testing and be conducted over longer periods so that the long-term benefits and tolerability of these different approaches can be evaluated.
0269-2813
923-939
Wilcox, Christopher
e2c4c36a-e2e5-43a5-9fd6-7198cc15dd53
Turner, Jeff
35309b03-e48a-4ab4-9535-e7ed64badf24
Green, John
088ef2ae-4d78-46a6-9893-afe3ddda23b5
Wilcox, Christopher
e2c4c36a-e2e5-43a5-9fd6-7198cc15dd53
Turner, Jeff
35309b03-e48a-4ab4-9535-e7ed64badf24
Green, John
088ef2ae-4d78-46a6-9893-afe3ddda23b5

Wilcox, Christopher, Turner, Jeff and Green, John (2014) Systematic review: the management of chronic diarrhoea due to bile acid malabsorption. Alimentary pharmacology & therapeutics, 39 (9), 923-939. (doi:10.1111/apt.12684).

Record type: Review

Abstract

Background
Bile acid malabsorption (BAM) is a common, yet under-recognised, cause of chronic diarrhoea, with limited guidance available on the appropriate management of patients with BAM.

Aim
To summarise the evidence supporting different treatments available for patients with bile acid malabsorption, noting their impact on clinical outcomes, tolerability and associated side effects.

Methods
A literature search was conducted through PubMed, the Cochrane Database of Systematic Reviews and Scopus. Relevant articles studied patients who had been diagnosed with BAM and were clinically assessed before and after therapy.

Results
A total of 30 relevant publications (1241 adult patients) were identified, which investigated the clinical response to drugs, including colestyramine, colestipol, colesevelam, aluminium hydroxide and obeticholic acid. The most commonly used diagnostic test of bile acid malabsorption was the SeHCAT test (24 studies). Colestyramine treatment was by far the most studied of these agents, and was successful in 70% of 801 patients (range: 63–100%).

Conclusions
Colestyramine and colestipol are generally effective treatments of gastrointestinal symptoms from BAM, but may be poorly tolerated and reduce the bioavailability of co-administered agents. Alternative therapies (including colesevelam and aluminium hydroxide) as well as dietary intervention may also have a role, and the promising results of the first proof-of-concept study of obeticholic acid suggest that its novel approach may have an exciting future in the treatment of this condition. Future trials should employ accurate diagnostic testing and be conducted over longer periods so that the long-term benefits and tolerability of these different approaches can be evaluated.

This record has no associated files available for download.

More information

e-pub ahead of print date: 6 March 2014
Published date: 1 May 2014

Identifiers

Local EPrints ID: 471181
URI: http://eprints.soton.ac.uk/id/eprint/471181
ISSN: 0269-2813
PURE UUID: bcdd0c10-6cc6-48c0-90ed-7a5fc96ea48b

Catalogue record

Date deposited: 31 Oct 2022 17:31
Last modified: 16 Mar 2024 21:48

Export record

Altmetrics

Contributors

Author: Jeff Turner
Author: John Green

Download statistics

Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.

View more statistics

Atom RSS 1.0 RSS 2.0

Contact ePrints Soton: eprints@soton.ac.uk

ePrints Soton supports OAI 2.0 with a base URL of http://eprints.soton.ac.uk/cgi/oai2

This repository has been built using EPrints software, developed at the University of Southampton, but available to everyone to use.

We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we will assume that you are happy to receive cookies on the University of Southampton website.

×